- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Metastatic pancreatic adenocarcinoma (mPAC)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 1.4KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 1.2KB)
Irinotecan – November 2024
Irinotecan; Solution for I.V. infusion containing nanoliposomal irinotecan (as sucrosofate) 43 mg in 10 mL; Onivyde®
Last updated
30 May 2025